By John Perkins
If you work in MedTech marketing, there is a good chance you spend a meaningful amount of time on LinkedIn company page content. Writing posts, getting them approved, making sure the messaging is right, the imagery is on brand, the compliance box is ticked. It is a real investment of time and organisational energy.
So here is a question worth considering: how many of your ideal customers actually see any of it?
The answer, according to the most comprehensive LinkedIn algorithm research available (the Algorithm Insights 2026 report just published by Richard van der Blom), is far fewer than most marketing teams assume. LinkedIn organic reach for company pages has been in structural decline for years, and the 2026 data makes that impossible to ignore.
The 2026 Algorithm Insights Report by Richard van der Blom, based on analysis of over 1.3 million LinkedIn posts, includes feed composition data tracking how LinkedIn has allocated its real estate between content types since 2021. The data is brutal.
In 2021, organic company content made up 6% of what users saw on mobile and 7% on desktop. By 2026, those figures have fallen to 2% on mobile and just 1% on desktop.
In other words, for every 100 posts a LinkedIn user scrolls past on their desktop feed, just one is an organic company page post. On mobile, it is two.
All that effort. All that approval time. One post in a hundred.
Source: Algorithm Report 2026 — Richard van der Blom
SparkLife's experience confirms this data. We see it consistently when we conduct LinkedIn audits for MedTech clients.
One client came to us with over 6,500 LinkedIn company page followers. Around 14% of those followers were healthcare professionals, their core target audience. Every time they posted organically, approximately 10% of all followers saw the post. That sounds reasonable until you follow the numbers through.
Of the followers actually seeing each post, only 1.4% were the HCPs they were trying to reach. That works out to roughly 80 to 90 ideal customers per post, at best.
We have seen the same pattern across LinkedIn audits of diagnostics companies, surgical device manufacturers, and imaging technology providers. The follower count looks encouraging in the dashboard. The Ideal Customer Profile (ICP) penetration, when you actually calculate it, tells a very different story.
And then there is the time cost. In most MedTech marketing teams, a company page post does not just get written and published. It goes through legal review, clinical sign-off, brand checks, and often senior leadership approval. A single post can absorb several hours of skilled team time. For 80 to 90 ideal customers reached, that is a very high cost per impression.
There is a phrase we use with clients that captures it well. A company page post is a bit like putting something up in your office reception. Everyone inside the building sees it. The CEO feels good about it. Very few of your actual customers ever walk past.
While LinkedIn organic company content has been shrinking, something else has been growing. Promoted company posts (as content or straight ads) now account for 29% of the mobile feed and 35% of the desktop feed.
Put that alongside the 2% and 1% organic company figures and the picture becomes very clear. LinkedIn paid advertising and promoted content now receives roughly ten times the feed share of organic company posts on desktop, and around fifteen times on mobile.
This is not an accident. LinkedIn is a commercial business. It has been systematically redirecting feed space toward paid content for years, and the 2026 data shows that process is well advanced. The platform is not malfunctioning. It is working exactly as designed.
It is important to be clear about what this data does and does not mean.
It does not mean LinkedIn is the wrong channel for MedTech. It remains the only B2B platform with the targeting precision to reach decision makers by job title, function, seniority, company size, and professional skills. For a sector where the buying audience is small, highly specialised, and spread across multiple organisational roles, that targeting capability is genuinely valuable.
What the data shows is that organic company posts are not the right mechanism for reaching that audience at scale.
When we have applied a LinkedIn paid advertising strategy for MedTech clients, the results have been impressive. FundamentalXR saw a 12x increase in LinkedIn engagement and a 4x reduction in cost per engagement. VP Med Group achieved a cost per lead more than ten times better than benchmark, with genuine engagement from the right decision makers, not inflated numbers driven by employee networks and competitor clicks.
Organic company posts still have a role. They contribute to your page’s topical identity, which affects how LinkedIn classifies and distributes your content. They give your team and leadership visibility of what the brand is saying. And they provide creative assets that can be amplified through paid campaigns.
But they should not be the primary mechanism for reaching your ICP. And they should not absorb the majority of your content team’s time if that time is not backed by paid distribution.
The practical reframe is this: treat organic posts as the foundation, and LinkedIn advertising as the amplification layer that actually gets your content in front of the right people. LinkedIn’s targeting means you can reach procurement leads, clinical directors, and VP-level commercial decision makers directly, bypassing the limitations of your follower base entirely.
If you are not sure how much of your current organic activity is actually reaching your ICP, the answer is probably fewer than you think. A LinkedIn audit will give you the real numbers, and in our experience, those numbers consistently make the case for a different approach more clearly than any general guidance can.
We offer LinkedIn audits specifically for MedTech companies, showing you exactly who is seeing your content, what proportion are genuine prospects, and where the gap between your organic activity and your ICP is largest.
Get in touch to find out more.
Data referenced in this post is drawn from the Algorithm Insights 2026 report by Richard van der Blom, based on analysis of over 1.3 million LinkedIn posts collected between September 2025 and February 2026.
If you've enjoyed this blog post, sign up to our newsletter to receive more content like this from the SparkLife experts.
At SparkLife we help healthcare marketers reach and engage with more people, using our proven SparkLife marketing system.
Founded by John Perkins and Carolyn Kelday, we bring a unique combination of decades of healthcare expertise and cutting-edge digital knowledge to global life sciences companies.
